INSUBCONTINENT EXCLUSIVE:
Company logo | Image: Facebook1 min read Last Updated : Sep 13 2024 | 8:25 PM IST
Akums Drugs and Pharmaceuticals on Friday said it has
received patent for a formulation for Sickle Cell Disease (SCD).
The company has received a patent from India patent office for its room
temperature stable oral suspension of Hydroxyurea, a formulation aimed at managing SCD.
"Our constant endeavor is to work on affordable
medicines for Orphan Drugs and reduce dependency on imported medicines ensuring patient safety from rare diseases with timely and necessary
treatment," Akums Managing Director Sanjeev Jain said in a statement.
SCD, a genetic blood disorder, leads to severe health complications
such as anaemia, frequent pain episodes and other debilitating symptoms, affecting millions worldwide, especially in India and
this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)First
Published: Sep 13 2024 | 8:25 PMIST
